Unethical human experimentation in the United States
In 1953, the AEC ran several studies at the University of Iowa on the health effects of radioactive iodine in newborns and pregnant women. In one study, researchers gave pregnant women from of iodine-131, in order to study the women's aborted embryos in an attempt to discover at what stage, and to what extent, radioactive iodine crosses the placental barrier. In another study, they gave 25 newborn babies (who were under 36 hours old and weighed from ) iodine-131, either by oral administration or through an injection, so that they could measure the amount of iodine in their thyroid glands, as iodine would go to that gland.
Iodine-131
A common treatment method for preventing iodine-131 exposure is by saturating the thyroid with regular, non-radioactive iodine-127, as an iodide or iodate salt. Free elemental iodine should not be used for saturating the thyroid because it is a corrosive oxidant and therefore is toxic to ingest in the necessary quantities. The thyroid will absorb very little of the radioactive iodine-131 after it is saturated with non-radioactive iodide, thereby avoiding the damage caused by radiation from radioiodine. The most common method of treatment is to give potassium iodide to those at risk. The dosage for adults is 130 mg potassium iodide per day, given in one dose, or divided into portions of 65 mg twice a day. This is equivalent to 100 mg of iodine, and is about 700 times bigger than the nutritional dose of iodine, which is 0.150 mg per day (150 micrograms per day). See potassium iodide for more information on prevention of radioiodine absorption by the thyroid during nuclear accident, or for nuclear medical reasons. The FDA-approved dosing of potassium iodide for this purpose are as follows: infants less than 1 month old, 16 mg; children 1 month to 3 years, 32 mg; children 3 years to 18 years, 65 mg; adults 130 mg. However, some sources recommend alternative dosing regimens.